In this episode, Joe interviews renowned chemist, filmmaker, and journalist, Hamilton Morris. After originally backing down from its first attempt in 2022, the DEA is once again looking to apply schedule I status to two lesser-known compounds: DOI (2,5-dimethoxy-4-iodoamphetamine) and DOC (2,5-dimethoxy-4-chloroamphetamine). For decades, DOI and DOC have been incredible tools for researchers studying serotonin […]
The post Is the DEA Sabotaging Psychedelic Research? Inside the Push to Schedule DOI and DOC appeared first on Psychedelics Today.
